| Literature DB >> 33666082 |
Huan Zhang1, Huanying Zheng2, Jinying Zhu1, Qiao Dong1, Jin Wang3, Huahao Fan4, Yangzhen Chen4, Xi Zhang1, Xiaohu Han1, Qianlin Li3, Jiahai Lu3, Yigang Tong4, Zeliang Chen1,3,4.
Abstract
The outbreak of coronavirus disease 2019 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has posed a serious threat to global public health. The mechanism of pathogenesis and the host immune response to SARS-CoV-2 infection are largely unknown. In the present study, we applied a quantitative proteomic technology to identify and quantify the ubiquitination changes that occur in both the virus and the Vero E6 cells during SARS-CoV-2 infection. By applying label-free, quantitative liquid chromatography with tandem mass spectrometry proteomics, 8943 lysine ubiquitination sites on 3086 proteins were identified, of which 138 sites on 104 proteins were quantified as significantly upregulated, while 828 sites on 447 proteins were downregulated at 72 h post-infection. Bioinformatics analysis suggested that SARS-CoV-2 infection might modulate host immune responses through the ubiquitination of important proteins, including USP5, IQGAP1, TRIM28, and Hsp90. Ubiquitination modification was also observed on 11 SAR-CoV-2 proteins, including proteins involved in virus replication and inhibition of the host innate immune response. Our study provides new insights into the interaction between SARS-CoV-2 and the host as well as potential targets for the prevention and treatment of COVID-19.Entities:
Keywords: LC-MS; coronavirus disease 2019; severe acute respiratory syndrome coronavirus 2; ubiquitome
Year: 2021 PMID: 33666082 PMCID: PMC7945586 DOI: 10.1021/acs.jproteome.0c00758
Source DB: PubMed Journal: J Proteome Res ISSN: 1535-3893 Impact factor: 4.466
Figure 1Experimental strategy and virus infection. (A) A workflow diagram for the identification of Kub sites in Vero E6 cells. (B) Vero E6 cells infected with SARS-CoV-2 at an MOI of 5.0 or mock-infected. 40× magnification.
Figure 2Overview of ubiquitome data in SARS-CoV-2-infected cells. (A) Distribution of tryptic peptide lengths. (B) Number of Kub sites per protein. (C,D) Numbers of proteins and sites that were identified and quantified by MS/MS. (E) Numbers of sites (left) and proteins (right) that met the threshold criterion (i.e., a fold change >2 or <0.5). (F) Crosstalk between proteomics data (LQ) and protein ubiquitination-modified omics data (LP), with Log2 protein virus-infected/mock-infected ratio as the vertical (y) axis and log2 Kub virus-infected/mock-infected ratio as the horizontal (x) axis.
Figure 3Sequence analysis of the ubiquitinated proteins in Vero E6 cells infected with SARS-CoV-2. (A) Enriched ubiquitination motif logos were produced by the Motif-X program and MoMo program. The size of the single letters refers to the frequency of the amino acid residue at that position. (B) Heat map of the amino acids surrounding Kub sites.
Figure 4Classification of the identified proteins containing upregulated and downregulated Kub sites. (A,B) Subcellular localization of proteins and (C,D) COG annotation of proteins.
Figure 5Functional enrichment analysis of identified proteins containing upregulated and downregulated Kub sites. BPs, CCs, and MFs.
Figure 6Clustering analysis of identified proteins containing differentially expressed Kub sites. Modified sites were classified into four classes based on fold change. Heat maps showing the results of a cluster analysis of data from the BPs, CCs, and MFs. Red indicates upregulated and blue indicates downregulated.
Figure 7Protein–protein interaction networks. Different colors represent the differential modification of proteins (blue means downregulated protein and red means upregulated protein). The circle size represents the number of differentially modified proteins and their interacting proteins. The larger the circle, the more proteins it interacts with, indicating that the protein is more important in the network. To clearly show the protein interactions, the top 50 proteins were screened out, and the interaction network with the closest interactions was mapped.
Ubiquitinated SARS-CoV-2 Proteins and Sites
| identified SARS-CoV-2 | identified sites |
|---|---|
| spike glycoprotein (S) | 41, 97, 150, 187, 195, 202, 206, 304, 310, 386, 417, 424, 458, 462, 529, 535, 558, 776, 786, 790, 795, 811, 814, 835, 933, 986, 1028, 1038, 1086, 1157, 1181,1191, 1255, 1266, 1269 |
| protein 3a (3a) | 16, 21, 132 |
| envelope small membrane protein (E) | 63 |
| membrane protein (N/A) | 162, 166, 180, 205 |
| non-structural protein 6 (6) | 42, 48 |
| protein 7a (7a) | 32, 85 |
| non-structural protein 8 (N/A) | 53 |
| nucleoprotein (N) | 61, 65, 143, 169, 233, 266, 342, 347, 355, 361, 375, 388, 405 |
| protein 9b (N/A) | 4, 40, 59, 67, 80, 97 |
| uncharacterized protein 14 (ORF14) | 10 |
| replicase polyprotein 1ab (rep) | 72, 210, 225, 247, 258, 292, 458, 497, 500, 510, 518, 527, 564, 625, 634, 636, 669, 672, 684, 699, 701, 714, 734, 851, 1124, 1233, 1305, 1315, 1387, 1396, 1529, 1745, 1753, 1795, 1855, 1860, 1878, 2148, 2191, 2200, 2478, 2533, 2610, 2757, 2849, 3213, 3215, 3324, 3573, 3839, 3843, 3850, 3861, 3988, 4221, 4433, 4465, 4552, 4818, 4822, 4943, 4969, 5455, 5738, 5908, 6874 |
Figure 8Ubiquitination sites in the functional domains of SARS-CoV-2 proteins. The red lines represent the ubiquitinated lysine sites.
Figure 9SARS-CoV-2 infection regulates type I IFN immune response by modulating USP5 ubiquitination. (A) Ubiquitination of USP5 was significantly downregulated and the expression of USP5 was upregulated following SARS-CoV-2 infection. (B) Integrated band density analysis on ubiquitination and expression of USP5, and the p value was calculated by the two-sample two-tailed T-test method. ** indicates p ≤ 0.01. (C–F) USP5 suppresses the virus-induced type I IFN signaling pathway.
Figure 10Schematic diagram of the possible regulatory mechanism. (A) Downregulated USP5 ubiquitination leads to increased USP5 expression, which promotes RIG-I K11 ubiquitination modification and inhibits the IFN-I pathways by recruiting STUB1. (B) K48 ubiquitin of IQGAP1 is downregulated, resulting in increased IQGAP1 expression and inhibition of IFN-I production. (C) The increase in Akt may affect the downstream mTOR protein through a multistep stimulatory modification process, which in turn acts on STAT3 and reduces the ubiquitination of STAT3. The reduction of JAK1 ubiquitination may increase the expression of Akt protein and reduce the ubiquitination of STAT3 protein.